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Discussion
Dr Cameron D. Wright (Boston, Mass). Thank you, Dr Huang.
That was an excellent presentation. The paper was likewise clear,
concise, and quite informative.
The authors describe a relatively modern cohort of patients
with locally advanced thymomas, those with stage IVA disease,
treated in a fashion relatively similarly, and we all recognize there
is no true standard therapy for these particular patients. After
receiving induction chemotherapy, these 18 patients had a high
complete resection rate, minimal morbidity, and no mortality. The
survival was quite good at 78% at 5 years. I have a note of caution,
though. The median follow-up was only 32 months, and these
tumors do have an ability to recur more than 5 years after resec-
tion. Therefore, this information is somewhat guarded. The authors
conclude that induction chemotherapy followed by resection is
safe and efficacious and probably represents the appropriate ther-
apy.
I have 5 questions for the authors. First, was there any hint as
to which chemotherapy was the best? PAC was the most common.
That is certainly very popular. Did you have any inkling that that
might be the best chemotherapy for this particular disease? Give us
the benefit of your experience.
Second, are there any patients on whom you do not operate
with stage IVA disease? You told us those on whom you do
operate, but not those on whom you do not.
Third, how extensive should the pleurectomy be? Should we
just do local pleural resection of the grossly visible metastases or
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should we do a complete pleurectomy when we identify even one
or two pleural metastases?
Fourth, were there any near-complete responses radiographi-
cally or, even more importantly, pathologically, and was there any
evidence of necrosis in your pathologic specimens from this in-
duction chemotherapy, signifying some benefit for this chemother-
apy?
Finally, why not give chemotherapy postoperatively to the
patients who responded preoperatively? Sixty-seven percent re-
sponded preoperatively. You identified that biologically. It is an
aggressive tumor that has already metastasized. Why not give
more chemotherapy to those who have proven to have had some
benefit?
Dr Huang. Thank you, Dr Wright. The most frequent combi-
nation of chemotherapy used in our series was PAC based on the
preferences of the treating oncologist as well as data from Loehrer
and associates1,2 demonstrating the efficacy of this combination as
well as its superiority to alternative regimens such as cisplatin and
etoposide and ifosfamide.
As this was a retrospective review of a surgical database, this
study includes only those patients who underwent resection. Pa-
tients with stage IVA disease who may not have responded to
induction therapy or who were otherwise not deemed to be surgical
candidates were not included in this analysis; therefore, no con-
clusions can be drawn regarding contraindications to surgery.
The consensus among the surgeons in our group is to do a local
resection of each individual pleural lesion, with the goal of attain-
ing a complete resection while limiting the amount of pulmonary
resection needed. We generally do not perform a complete parietal
pleurectomy. In cases in which the pleural component is very
extensive and confluent, EPP may offer the only possibility of
achieving a complete resection.
Although there were no radiographic complete responses based
on the RECIST criteria, 5 of the 10 responders did have evidence
of treatment effect ranging up to 50% necrosis in the specimens,
confirming the chemosensitivity of this tumor. There were no
pathologic complete responses, re-emphasizing the point that med-
ical therapy alone is probably insufficient and that surgery remains
essential in the treatment of thymoma.
Although several reports have demonstrated the efficacy of
induction chemotherapy, there are no data regarding the utility of
postoperative chemotherapy in thymoma. It is reasonable to con-
sider postoperative chemotherapy in patients with incomplete re-
sections who responded to induction therapy. Whether postopera-
tive chemotherapy is of any benefit to patients with complete
resections is unknown.
Dr Federico Venuta (Rome, Italy) What was the reason for
incompleteness of resection? Was it related to the primary tumor
or to the pleural dissemination? Were there patients with pleural
effusions in the population of patients receiving pleurectomy?
Probably it was my fault, but I did not get the survival of patients
receiving incomplete resections.
Dr Huang. In 4 of the 6 incomplete resections, only minimal
disease was left behind owing to involvement of either the great
vessels or both phrenic nerves. In each of these 4 cases, tumor was
shaved off the critical involved structures, necessarily leaving
minimal residual disease behind. In the other 2 incomplete resec-
tions, gross disease remained owing to invasion of the heart in 1
case and the discovery of bilateral pleural disease in the other. Data
regarding pleural effusions were not captured in our database.
There was a trend toward a survival benefit for complete
resection. The survival was 86% in macroscopically complete
resections and 50% in those with incomplete resections. However,
with only 3 events, these numbers are not statistically significant.
Dr Philip Linden. (Boston, Mass) Did you make any effort to
determine what preoperative factors might influence long-term
survival; that is, did the degree of response to chemotherapy
correlate with survival, comorbid conditions, or type of operation
at all? It would be very useful to know to try to predict which
patients might do well long term.
Dr Huang. This cohort clearly represents a preselected group
of patients. In general, these were very young and otherwise
healthy patients with very little comorbidity. The small number of
patients in this cohort precluded the performance of a multivariate
analysis of prognosticating factors.
Dr Walter Weder. (Zurich, Switzerland) What was the sur-
vival difference between those who underwent EPP compared with
pleurectomy?
Dr Huang. With only 3 events for analysis, there was a
marginally better survival for pleurectomy than EPP that was not
statistically significant.
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